FABP3 and neoplasm: Additionally, we generated a new high/low risk index to combine FABP3, CD36 and RAETE1. Patients were categorized into a high-risk group for progression when tumor had high expression levels of FABP3 and CD36 and low expression of RAETE1. The new index assigns the expression of any of these 3 genes, as a risk factor of 1, any 2 of the 3 genes, a risk factor of 2, and the combined expression of all 3, a risk factor of 3.